[opensourcepharma] OSP @ RHH 2015 will happen Sep 1-3

Tue Jun 9 11:46:29 UTC 2015

Bernard's use of the phrase "the recipe had been lost" is very apt, and is
to my mind an important feature of open source - if you want the work
you've done to have a long life, put it in the public domain. There are
openly available databases like Chembl and Pubchem that possess the kind of
archival function that tracks what is known about which molecule vs which
target. The added value of open source pharma on top of that is to keep
research projects alive - the What Would We Have Done Next type of insights
from the people involved that can be priceless.

FYI some major repositioning work was recently carried out
<http://www.malariajournal.com/content/13/1/143>in the malaria field by MMV
with good initial results but with a cautionary note about the difficulty
of the hits proceeding further, given that in many cases you're switching
target from human to pathogen.

Best,
Mat

On 9 June 2015 at 19:50, Dimitrios Tzalis <dtzalis at taros.de> wrote:

> Dear Jay,
>
> this indeed is a very interesting approach and has gotten quite some
> attention for quite some time for obvious reasons.  There are ongoing
> activites in this area in the US as well as in Europe. There are quite a
> few initiatives where ADMET data is being made available on potential drug
> candidates in an Open Source approach. There was last year good review in
> 2013 on this topic by Minna Allarakhia
>
>
> http://www.academia.edu/4964147/Open-source_approaches_for_the_repurposing_of_existing_or_failed_candidate_drugs
>
>
> Kind regards,
>
> Dimitrios
>
> Von meinem iPad gesendet
>
> Am 09.06.2015 um 03:02 schrieb "Jaykumar Menon, Prof." <
> jaykumar.menon at mcgill.ca>:
>
>  Dear Peter,
>
>
>
> Thanks for the note and all the superb effort!
>
>
>
> And dear all,
>
>
>
> There is so much to discuss and plan and make sense of, as the open source
> meme seems to be catching on.  (And a quick personal apologia - I’ve been
> buried in things operational – trying to add some heft and muscle to this
> discussion and movement, so sorry for my relative silence of late on the
> email list-serv.)  For the meeting at the Castle, as you can see from the
> spreadsheet, we are already at 14 attendees, a mix of  “new” and “old”
> blood (i.e. those who attended Bellagio and those who did not), hailing
> from San Francisco (Linux Foundation) to Seattle (a special person from
> Gates) to Oxford (Structural Genomics), with some heavy hitters, so let us
> know if you are interested soon, as this is again a small venue, and we are
> trying to get the optimal mix.  Suggestions of people are also welcome.
>
>
>
> As those of you who were at Bellagio remember, this is a special group,
> and a special colloquy and movement, operating in a realm that is at the
> cutting edge of the cutting edge, yet animated by human need.  It is a
> union of those adept at concretizing dreams.  And it is superfun, a bonding
> experience.  Thanks again to Peter for securing such an unbelievable spot.
>
>
>
> And as a precis and discussion starter, a question, perhaps foolish and
> ill-informed, considering the vast expertise in this group, but posed in
> the spirit of risk-taking and thinking big, is appended below.
>
>
>
> With warm regards,
>
> Jaykumar
>
>
>
> *Repurposing (admittedly imprecise and perhaps inaccurate description):*
>   Repurposed drugs offer the prospect of huge cost savings.  The goal of
> repurposing is to deploy approved drugs or abandoned clinical candidates in
> new disease areas.  Directing such drugs – particularly those that are
> fully approved and off patent - towards new diseases can deliver cures at a
> fraction of the cost of developing a new drug.  This is due to savings in
> R&D expense and reduced clinical trial requirements.
>
>
>
> A question came up recently in a discussion with a funder, and we novices
> didn’t know the answer, and I thought I’d take it to the group mind.
>
>
>
> Would it make any sense to have a grand and almost comprehensive
> repurposing project, an Apollo project of sorts, where we look at
> essentially all/large numbers of generic drugs, to see their applicability
> against a particular condition (or many) of (public) health need?  Has it
> already been adequately done?  (There have been  efforts from NIH NCATS,
> working with under-patent drug candidates from pharma companies, but
> evidently not with generics and approved drugs, and other efforts too).
> Would it be at all needed, feasible and fruitful?  If so, crowdsourcing and
> openness would seem to be essential.  It is thus a natural fit for those
> intrigued by open source pharma.
>
>
>
> j
>
>
>
> *From:* Peter Kolb [mailto:peter.kolb at uni-marburg.de
> <peter.kolb at uni-marburg.de>]
> *Sent:* Monday, June 08, 2015 1:50 PM
> *To:* opensourcepharma at lists.okfn.org
> *Cc:* Jaykumar Menon, Prof.; Matthew Todd
> *Subject:* OSP @ RHH 2015 will happen Sep 1-3
>
>
>
> Dear past and future OSP participants,
>
> The 2015 meeting will take place on September 1-3, 2015, in castle
> Rauischholzhausen <https://goo.gl/maps/TmERX>, near Marburg (greater
> Frankfurt area), Germany.  Here are some key facts to assist in your
> planning:
>
>    - Arrival is possible from Aug 31, 10am. Departure is on Sep 3 after
>    lunch. The conference program will run from Sep 1 morning until Sep 3 noon.
>    - Please sign up at http://tinyurl.com/osprhh by June 30 in order to
>    participate. This spreadsheet also allows you to record dietary preferences
>    as well as arrival and departure times.
>    - The easiest travel option is to fly into Frankfurt airport (FRA),
>    then take a train <http://www.bahn.de/p_en/view/index.shtml> to
>    Marburg (approx. 90 mins), followed by a short cab ride to the castle. More
>    detailed instructions will follow to participants at a later time.
>    - Accommodation as well as meals and coffee breaks will be provided at
>    the castle.
>    - We have secured some sponsorship and are trying to secure more.  The
>    worst-case scenario, in case we completely fail to do so, will be a lodging
>    fee of EUR 250 per person (covering all accommodation and meals for the 3-4
>    days, which is quite reasonable). Please do not let it be an impediment to
>    registering initially; if you need to drop out later, that will be all
>    right.
>
> If you have any questions, please do not hesitate to write!
>
> Looking forward to a fruitful meeting in September,
> Jay, Mat & Peter
>
>  --
>
>
>
> P e t e r   K o l b
>
> Emmy Noether Group Leader
>
> Pharmaceutical Chemistry @ Philipps-University Marburg
>
> Tel +49 6421 28 25908 | Fax +49 6421 28 28994
>
> http://www.kolblab.org
>
>
>
> Chair | GLISTEN: COST Action CM1207
>
> http://www.glisten-gpcr.eu/
>
>
>
> Editor | Journal of Postdoctoral Affairs
>
> http://www.postdocjournal.com
>
>  _______________________________________________
> opensourcepharma mailing list
> opensourcepharma at lists.okfn.org
> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>
>
> _______________________________________________
> opensourcepharma mailing list
> opensourcepharma at lists.okfn.org
> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>
>

-- 
MATTHEW TODD | Associate Professor
School of Chemistry | Faculty of Science

THE UNIVERSITY OF SYDNEY
Rm 519, F11 | The University of Sydney | NSW | 2006
T +61 2 9351 2180  | F +61 2 9351 3329  | M +61 415 274104
E matthew.todd at sydney.edu.au | W
http://sydney.edu.au/science/chemistry/research/todd.html | W
http://opensourcemalaria.org/

CRICOS 00026A
This email plus any attachments to it are confidential. Any unauthorised
use is strictly prohibited. If you receive this email in error, please
delete it and any attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20150609/d5a01d4c/attachment-0002.html>